Differential regulation of p73 variants in response to cisplatin treatment in SH-SY5Y neuroblastoma cells

International Journal of Oncology

Volumn 29, Issue 1, 2006, Pages 147-154

  Million, Karine ^a   Horvilleur, Émilie ^a   Goldschneider, David ^a   Agina, Malik ^a   Raguénez, Gilda ^a   Tournier, Frédéric ^b   Bénard, Jean ^a   Douc Rasy, Sétha ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Cisplatin; Neuroblastoma; p53; p73

Indexed keywords

ANTINEOPLASTIC AGENT; CDKN1A PROTEIN, HUMAN; CELL CYCLE PROTEIN; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; DNA BINDING PROTEIN; GADD45A PROTEIN, HUMAN; ISOPROTEIN; MESSENGER RNA; NUCLEAR PROTEIN; PROTEIN P53; SMALL INTERFERING RNA; TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN P73;

ALTERNATIVE RNA SPLICING; APOPTOSIS; ARTICLE; DOSE RESPONSE; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; NEUROBLASTOMA; RNA INTERFERENCE; RNA STABILITY; TIME; TUMOR CELL LINE;

ALTERNATIVE SPLICING; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CISPLATIN; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEUROBLASTOMA; NUCLEAR PROTEINS; PROTEIN ISOFORMS; RNA INTERFERENCE; RNA STABILITY; RNA, MESSENGER; RNA, SMALL INTERFERING; TIME FACTORS; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 36048983370     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.29.1.147     Document Type: Article

References (37)

1. Keshelava N, Seeger RC, Groshen S and Reynolds CP: Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. Cancer Res 58: 5396-5405, 1998.
2. Keshelava N, Zuo JJ, Chen P, Waidyaratne SN, Luna MC, Gomer CJ, Triche TJ and Reynolds CP: Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines. Cancer Res 61: 6185-6193, 2001.
3. Tweddle DA, Malcolm AJ, Bown N, Pearson AD and Lunec J: Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line. Cancer Res 61: 8-13, 2001.
4. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A, Minty A, Chalon P, Lelias JM, Dumont X, Ferrara P, McKeon F and Caput D: Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90: 809-819, 1997.
5. Jost CA, Marin MC and Kaelin WG Jr: p73 is a simian [correction of human] p53-related protein that can induce apoptosis. Nature 389: 191-194, 1997.
6. Melino G, De Laurenzi V and Vousden KH: p73: Friend or foe in tumorigenesis. Nat Rev Cancer 2: 605-615, 2002.
7. Stiewe T and Putzer BM: Role of p73 in malignancy: tumor suppressor or oncogene? Cell Death Differ 9: 237-945, 2002.
8. Terrinoni A, Ranalli M, Cadot B, Leta A, Bagetta G, Vousden KH and Melino G: p73-alpha is capable of inducing scotin and ER stress. Oncogene 23: 3721-3725, 2004.
9. Melino G, Bernassola F, Ranalli M, Yee K, Zong WX, Corazzari M, Knight A, Green DR, Thompson C and Vousden KH: P73 induces apoptosis via PUMA transactivation and Bax mitochondrial translocation. J Biol Chem 279: 8076-8083, 2004.
10. Terrasson J, Allart S, Martin H, Lulé J, Haddada H, Caput D and Davrinche C: p73-dependent apoptosis through death receptor: impairment by human cytomegalovirus infection. Cancer Res 65: 2787-2793, 2005.
11. Zaika AI, Slade N, Erster SH, Sansome C, Joseph TW, Pearl M, Chalas E and Moll UM: DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. J Exp Med 196: 765-780, 2002.
12. Moll UM and Slade N: p63 and p73: roles in development and tumor formation. Mol Cancer Res 2: 371-386, 2004.
13. Douc-Rasy S, Barrois M, Echeynne M, Kaghad M, Blanc E, Raguenez G, Goldschneider D, Terrier-Lacombe MJ, Hartmann O, Moll U, Caput D and Bénard J: DeltaN-p73alpha accumulates in human neuroblastic tumors. Am J Pathol 160: 631-639, 2002.
14. Goldschneider D, Blanc E, Raguenez G, Barrois M, Legrand A, Le Roux G, Haddada H, Bénard J and Douc-Rasy S: Differential response of p53 target genes to p73 overexpression in SH-SY5Y neuroblastoma cell line. J Cell Sci 117: 293-301, 2004.
15. Irwin MS, Kondo K, Marin MC, Cheng LS, Hahn WC and Kaelin WG Jr: Chemosensitivity linked to p73 function. Cancer Cell 3: 403-410, 2003.
16. Grob TJ, Novak U, Maisse C, Barcaroli D, Luthi AU, Pirnia F, Hugli B, Graber HU, De Laurenzi V, Fey MF, Melino G and Tobler A: Human deltaNp73 regulates a dominant negative feedback loop for TAp73 and p53. Cell Death Differ 8: 1213-1223, 2001. (Pubitemid 34048476)
17. Nakagawa T, Takahashi M, Ozaki T, Watanabe KK, Todo S, Mizuguchi H, Hayakawa T and Nakagawara A: Autoinhibitory regulation of p73 by Delta Np73 to modulate cell survival and death through a p73-specific target element within the Delta Np73 promoter. Mol Cell Biol 22: 2575-2585, 2002.
18. Balint E, Bates S and Vousden KH: Mdm2 binds p73 alpha without targeting degradation. Oncogene 18: 3923-3929, 1999.
19. Zeng X, Chen L, Jost CA, Maya R, Keller D, Wang X, Kaelin WG Jr, Oren M, Chen J and Lu H: MDM2 suppresses p73 function without promoting p73 degradation. Mol Cell Biol 19: 3257-3266, 1999.
20. Zhu J, Nozell S, Wang J, Jiang J, Zhou W and Chen X: p73 cooperates with DNA damage agents to induce apoptosis in MCF7 cells in a p53-dependent manner. Oncogene 20: 4050-4057, 2001.
21. Flores ER, Tsai KY, Crowley D, Sengupta S, Yang A, McKeon F and Jacks T: p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 416: 560-564, 2002.
22. Fillippovich I, Sorokina N, Gatei M, Haupt Y, Hobson K, Moallem E, Spring K, Mould M, McGuckin MA, Lavin MF and Khanna KK: Transactivation-deficient p73alpha (p73Deltaexon2) inhibits apoptosis and competes with p53. Oncogene 20: 514-522, 2001.
23. Vossio S, Palescandolo E, Pediconi N, Moretti F, Balsano C, Levrero M and Costanzo A: ΔN-p73 is activated after DNA damage in a p53-dependent manner to regulate p53-induced cell cycle arrest. Oncogene 21: 3796-3803, 2002.
24. Kartasheva N, Lenz-Bauer C, Hartmann O, Schäfer H, Eilers M and Dobbelstein M: ΔNp73 can modulate the expression of various genes in a p53-independent fashion. Oncogene 22: 8246-8254, 2003.
25. TIS21/PC23 is transactivated by ΔNp73a via p53 specifically in neuroblastoma cells. J Cell Sci 118: 1245-1253, 2005.
26. Gaiddon C, Lokshin M, Gross I, Levasseur D, Taya Y, Loeffler JP and Prives C: Cyclin-dependent kinases phosphorylate p73 at Threonine 86 in a cell cycle-dependent manner and negatively regulate p73. J Biol Chem 278: 27421-27431, 2003.
27. Zhou BP, Liao Y, Xia W, Spohn B, Lee MH and Hung MC: Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat Cell Biol 3: 245-252, 2001.
28. Goldschneider D, Blanc E, Raguenez G, Haddada H, Bénard J and Douc-Rasy S: When p53 needs p73 to be functional - forced p73 expression induces nuclear accumulation of endogenous p53 protein. Cancer Lett 197: 99-103, 2003.
29. Gong J, Costanzo A, Yang H-Q, Melino G, Kaelin W, Levrero M and Wang JYJ: The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 399: 806-809, 1999.
30. Senoo M, Manis JP, Alt FW and McKeon F: p63 and p73 are not required for the development and p53-dependent apoptosis of T cells. Cancer Cell 6: 85-89, 2004.
31. Vayssade M, Haddada H, Faridoni-Laurens L, Tourpin S, Valent A, Bénard J and Ahomadegbe JC: p73 functionally replaces p53 in Adriamycin-treated, p53-deficient breast cancer cells. Int J Cancer 116: 860-869, 2005.
32. Stiewe T, Theseling CC and Putzer BM: Transactivation-deficient ΔTA-p73 inhibits p53 by direct competition for DNA binding: implications for tumorigenesis. J Biol Chem 277: 14177-14185, 2002.
33. Levrero M, De Laurenzi V, Costanzo A, Gong J, Wang JY and Melino G: The p53/p63/p73 family of transcription factors: overlapping and distinct functions. J Cell Sci 113: 1661-1670, 2000.
34. Zhu X, Wimmer K, Kuick R, Lamb BJ, Motyka S, Jasty R, Castle VP and Hanash SM: N-myc modulates expression of p73 in neuroblastoma. Neoplasia 4: 432-439, 2002.
35. Nilsson JA and Cleveland JL: Myc pathways provoking cell suicide and cancer. Oncogene 22: 9007-9021, 2003.
36. Rossi M, Sayan AE, Terrinoni A, Melino G and Knight RA: Mechanism of induction of apoptosis by p73 and its relevance to neuroblastoma biology. Ann NY Acad Sci 1028: 143-149, 2004.
37. Donzelli E, Carfi M, Miloso M, Strada A, Galbiati S, Bayssas M, Griffon-Etienne G, Cavaletti G, Petruccioli MG and Tredici G: Neurotoxicity of platinum compounds: comparison of the effects of cisplatin and oxaliplatin on the human neuroblastoma cell line SH-SY5Y. J Neurooncol 67: 65-73, 2004.